Introduction
Intratumor heterogeneity is one of the recognized
characteristics of human tumors, which occurs on multiple levels,
including genetic, protein and macroscopic, in a wide range of
tumors, including breast, colorectal cancer (CRC), non-small cell
lung cancer (NSCLC), prostate, ovarian, pancreatic, gastric, brain
and renal clear cell carcinoma (1). Over the past decade, a number of
studies have focused on the heterogeneity found in primary tumors
and related metastases with the consideration that the evaluation
of metastatic rather than primary sites may be of clinical
relevance. Numerous reports have evaluated the genetic
heterogeneity in primary tumors and corresponding metastases in a
range of solid tumors, including breast cancer (2–9), CRC
(10–13) and NSCLC (14,15).
In CRC, the heterogeneity of the epidermal growth
factor receptor (EGFR) gene status and its downstream
signalling proteins, including KRAS, BRAF and
PIK3CA mutations, have been identified by comparing primary
tumors with corresponding metastases, respectively (10–13).
Baldus et al demonstrated particularly high rates of
heterogeneity between primary colorectal tumors and lymph node
metastases (10). Molinari et
al analyzed EGFR gene status and protein expression,
KRAS/BRAF mutations and PTEN expression in primary tumors
and metastases in 38 metastatic CRC patients, and found EGFR
gene deregulation in 69.4% of primary tumors and 80.6% of
metastases, and KRAS mutations in 43.2% of primary tumors
and 40.5% of metastases (11).
However, the heterogeneity in primary CRC and corresponding
metastases at the genome-wide gene expression level has not been
extensively investigated.
Therefore, in the present study, we investigated the
heterogeneity in primary colon carcinoma tissue and its
corresponding lymphatic and hepatic metastatic tissues obtained
from a female metastatic colon cancer patient, focusing on
genome-wide gene expression.
Patients and methods
Patient and tissue samples
Tumor specimens were obtained at initial surgery
from a 40-year-old female colon carcinoma patient with lymphatic
and hepatic metastases. Samples were snap-frozen and stored in
liquid nitrogen until use. Prior written informed consent was
obtained from the patient and the study received ethics board
approval at the First Affiliated Hospital, College of Medicine,
Zhejiang University, Hangzhou, China. The patient had not received
chemotherapy or radiation therapy prior to surgery. The
histological type was determined according to the WHO criteria. The
tumor was diagnosed as mucinous adenocarcinoma (T3N2M1).
Genome-wide gene expression analysis
RNA was extracted from tumor specimens. Total RNA of
homogenized tumor samples was prepared with TRIzol RNA extraction
reagent (Invitrogen) followed by purification using the RNeasy Mini
kit (Qiagen) according to the manufacturer’s instructions. A DNase
I (Qiagen) digestion step was included to eliminate genomic DNA.
The quality of the total RNA was examined for integrity using RNA
LabChips and the Agilent Bioanalyzer 2100 (Agilent Technologies),
and the concentration was measured using the Peqlab NanoDrop. Only
RNA with an RNA integrity number >6.5 was used for cDNA
synthesis. The one-cycle eukaryotic target labeling assay from
Affymetrix was used according to manufacturer’s instructions as
previously described (16,17). Data analysis was also performed as
previously described (16,17).
Statistical analysis
Hierarchical clustering of all microarray
experiments was performed based on all 54,675 probe sets
represented on the HGU133Plus2.0 array (Affymetrix) (P<0.04)
using positive correlation and complete linkage. Gene expression of
the primary tumor was compared with the median arrays of the paired
lymphatic metastatic and hepatic metastatic tumors from each
xenograft model in a paired t-test.
Results
Heterogeneity in primary colon carcinoma
and its paired lymphatic and hepatic metastases
Based on the results of the genome-wide gene
expression analysis, a paired t-test between the primary colon
carcinoma and its paired lymphatic metastasis revealed 190
differentially expressed probe sets with a fold change ≥20.
Clustering based on these 190 probe sets demonstrated a clear
distinction between primary colon carcinoma and its paired
lymphatic metastasis, with the majority of the probe sets (115 of
190) being downregulated in the lymphatic metastasis and only a
small number being upregulated (75 of 190) (Table I). A paired t-test between the
primary colon carcinoma and its paired hepatic metastasis revealed
150 differentially expressed probe sets with a fold change ≥20.
Clustering based on these 150 probe sets demonstrated a clear
distinction between primary colon carcinoma and its paired hepatic
metastasis, with the majority of probe sets (94 of 150) being
downregulated in the hepatic metastasis and only a very small
number being upregulated (56 of 150) (Table II). A paired t-test between
colon carcinoma lymphatic metastasis and hepatic metastasis
revealed 176 differentially expressed probe sets with a fold change
of only ≥10. Clustering based on these 176 probe sets demonstrated
a clear distinction between colon carcinoma lymphatic metastasis
and hepatic metastasis, with the majority of probe sets (114 of
176) being downregulated in the hepatic metastasis and only a very
small number being upregulated (62 of 176) (Table III).
 | Table IGenes differentially expressed in the
primary colon carcinoma specimen and its paired lymphatic
metastasis. |
Table I
Genes differentially expressed in the
primary colon carcinoma specimen and its paired lymphatic
metastasis.
| Probe set ID | Fold change | Gene symbol | Entrez gene | Gene title |
|---|
| 201847_at | 23.27895 | LIPA | 3988 | Lipase A, lysosomal
acid, cholesterol esterase |
| 203323_at | 20.588184 | CAV2 | 858 | Caveolin 2 |
| 203324_s_at | 25.194075 | CAV2 | 858 | Caveolin 2 |
| 203571_s_at | 23.1392 | C10 or f116 | 10974 | Chromosome 10 open
reading frame 116 |
| 203639_s_at | 69.52935 | FGFR2 | 2263 | Fibroblast growth
factor receptor 2 |
| 203697_at | 20.352211 | FRZB | 2487 | Frizzled-related
protein |
| 204010_s_at | 34.406235 | KRAS | 3845 | v-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog |
| 204035_at | 39.844757 | SCG2 | 7857 | Secretogranin II
(chromogranin C) |
| 204439_at | 46.355186 | IFI44L | 10964 | Interferon-induced
protein 44-like |
| 204802_at | 113.641525 | RRAD | 6236 | Ras-related
associated with diabetes |
| 204803_s_at | 41.770977 | RRAD | 6236 | Ras-related
associated with diabetes |
| 205151_s_at | 36.290764 | KIAA0644 | 9865 | KIAA0644 gene
product |
| 205625_s_at | 29.481396 | CALB1 | 793 | Calbindin 1, 28
kDa |
| 205696_s_at | 45.68169 | GFRA1 | 2674 | GDNF family receptor
α 1 |
| 205778_at | 28.692463 | KLK7 | 5650 | Kallikrein-related
peptidase 7 |
| 205818_at | 109.04431 | DBC1 | 1620 | Deleted in bladder
cancer 1 |
| 205830_at | 20.343859 | CLGN | 1047 | Calmegin |
| 206091_at | 25.613195 | MATN3 | 4148 | Matrilin 3 |
| 206340_at | 24.728613 | NR1H4 | 9971 | Nuclear receptor
subfamily 1, group H, member 4 |
| 206525_at | 25.197699 | GABRR1 | 2569 | γ-aminobutyric acid
(GABA) receptor, rho 1 |
| 206619_at | 34.690308 | DKK4 | 27121 | Dickkopf homolog 4
(Xenopus laevis) |
| 206877_at | 20.351955 | MXD1 | 4084 | MAX dimerization
protein 1 |
| 207254_at | 48.329205 | SLC15A1 | 6564 | Solute carrier family
15 (oligopeptide transporter), member 1 |
| 207509_s_at | 51.56186 | LAIR2 | 3904 | Leukocyte-associated
immunoglobulin-like receptor 2 |
| 207583_at | 40.26811 | ABCD2 | 225 | ATP-binding cassette,
sub-family D (ALD), member 2 |
| 207610_s_at | 23.911833 | EMR2 | 30817 | Egf-like module
containing, mucin-like, hormone receptor-like 2 |
| 208146_s_at | 89.68937 | CPVL | 54504 | Carboxypeptidase,
vitellogenic-like |
| 208261_x_at | 29.10015 | IFNA10 | 3446 | Interferon, α 10 |
| 208481_at | 26.099915 | ASB4 | 51666 | Ankyrin repeat and
SOCS box-containing 4 |
| 208791_at | 46.167988 | CLU | 1191 | Clusterin |
| 209406_at | 29.201277 | BAG2 | 9532 | BCL2-associated
athanogene 2 |
| 209792_s_at | 38.65837 | KLK10 | 5655 | Kallikrein-related
peptidase 10 |
| 209821_at | 205.30872 | IL33 | 90865 | Interleukin 33 |
| 210510_s_at | 27.80813 | NRP1 | 8829 | Neuropilin 1 |
| 210931_at | 24.963585 | RNF6 | 6049 | Ring finger protein
(C3H2C3 type) 6 |
| 211161_s_at | 30.307695 | COL3A1 | 1281 | Collagen, type III, α
1 |
| 211401_s_at | 20.871784 | FGFR2 | 2263 | Fibroblast growth
factor receptor 2 |
| 213238_at | 42.231457 | ATP10D | 57205 | ATPase, class V, type
10D |
| 213428_s_at | 44.14465 | COL6A1 | 1291 | Collagen, type VI,
α 1 |
| 213432_at | 189.0725 | MUC5B | 727897 | Mucin 5B,
oligomeric mucus/gel-forming |
| 213874_at | 60.066086 | SERPINA4 | 5267 | Serpin peptidase
inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 4 |
| 214044_at | 23.23853 | RYR2 | 6262 | Ryanodine receptor
2 (cardiac) |
| 214121_x_at | 28.547356 | PDLIM7 | 9260 | PDZ and LIM domain
7 (enigma) |
| 214146_s_at | 40.065388 | PPBP | 5473 | Pro-platelet basic
protein [chemokine (C-X-C motif) ligand 7] |
| 214453_s_at | 33.425632 | IFI44 | 10561 | Interferon-induced
protein 44 |
| 214567_s_at | 25.704966 | XCL1 | 6375 | Chemokine (C motif)
ligand 1 |
| | XCL2 | 6846 | Chemokine (C motif)
ligand 2 |
| 214769_at | 31.164827 | CLCN4 | 1183 | Chloride channel
4 |
| 214811_at | 62.246216 | RIMBP2 | 23504 | RIMS binding
protein 2 |
| 214823_at | 36.446995 | ZNF204 | 7754 | Zinc finger protein
204 pseudogene |
| 214952_at | 31.43681 | NCAM1 | 4684 | Neural cell
adhesion molecule 1 |
| 215081_at | 38.364174 | KIAA1024 | 23251 | KIAA1024 |
| 215318_at | 27.675882 | CG012 | 116829 | Hypothetical gene
CG012 |
| 215917_at | 27.72305 | SNPH | 9751 | Syntaphilin |
| 216039_at | 28.136038 | LOC100132832 | 100132832 | Postmeiotic
segregation increased 2-like 5-like |
| | LOC441259 | 392713 | PMS2 postmeiotic
segregation increased 2 (S. cerevisiae)-like |
| | LOC730324 | 441259 | Similar to
postmeiotic segregation increased 2-like 2 |
| | PMS2 | 5379 | PMS2 postmeiotic
segregation increased 2 (S. cerevisiae) |
| | PMS2L1 | 5380 | Postmeiotic
segregation increased 2-like 1 pseudogene |
| | PMS2L12 | 5383 | Postmeiotic
segregation increased 2-like 12 pseudogene |
| | PMS2L2 | 5387 | Postmeiotic
segregation increased 2-like 2 pseudogene |
| | PMS2L3 | 5395 | Postmeiotic
segregation increased 2-like 3 |
| | PMS2L5 | 730324 | Postmeiotic
segregation increased 2-like 5 |
| 216614_at | 38.53543 | | | |
| 217546_at | 59.020702 | MT1M | 4499 | Metallothionein
1M |
| 217664_at | 26.640495 | | | |
| 218720_x_at | 44.51107 | LOC652900 | 26470 | Similar to seizure
related 6 homolog (mouse)-like 2 isoform 1 |
| | SEZ6L2 | 652900 | Seizure related 6
homolog (mouse)-like 2 |
| 219396_s_at | 41.20278 | NEIL1 | 79661 | Nei endonuclease
VIII-like 1 (E. coli) |
| 219563_at | 28.401752 | C14 or f139 | 79686 | Chromosome 14 open
reading frame 139 |
| 219727_at | 29.042574 | DUOX2 | 50506 | Dual oxidase 2 |
| 219728_at | 23.185019 | MYOT | 9499 | Myotilin |
| 219768_at | 90.29275 | VTCN1 | 79679 | V-set domain
containing T cell activation inhibitor 1 |
| 219947_at | 43.223457 | CLEC4A | 50856 | C-type lectin
domain family 4, member A |
| 219949_at | 53.802288 | LRRC2 | 79442 | Leucine-rich repeat
containing 2 |
| 220086_at | 24.022339 | IKZF5 | 64376 | IKAROS family zinc
finger 5 (Pegasus) |
| 220160_s_at | 20.245548 | KPTN | 11133 | Kaptin (actin
binding protein) |
| 221195_at | 25.616514 | RNFT1 | 51136 | Ring finger
protein, transmembrane 1 |
| 222106_at | 26.959286 | PRND | 23627 | Prion protein 2
(dublet) |
| 222565_s_at | 60.40278 | PRKD3 | 23683 | Protein kinase
D3 |
| 222668_at | 114.43788 | KCTD15 | 79047 | Potassium channel
tetramerisation domain containing 15 |
| 222720_x_at | 23.61017 | C1 or f27 | 54953 | Chromosome 1 open
reading frame 27 |
| 223235_s_at | 76.54248 | SMOC2 | 64094 | SPARC related
modular calcium binding 2 |
| 223599_at | 21.029135 | TRIM6 | 117854 | Tripartite
motif-containing 6 |
| 223985_at | 27.464828 | FSD1L | 83856 | Fibronectin type
III and SPRY domain containing 1-like |
| 223999_at | 26.675077 | PPIL2 | 23759 | Peptidylprolyl
isomerase (cyclophilin)-like 2 |
| 224098_at | 32.526546 | | | |
| 224348_s_at | 34.73594 | | | |
| 224533_s_at | 77.99536 | C6 or f142 | 90523 | Chromosome 6 open
reading frame 142 |
| 225627_s_at | 23.322224 | CACHD1 | 57685 | Cache domain
containing 1 |
| 225728_at | 26.672054 | SORBS2 | 8470 | Sorbin and SH3
domain containing 2 |
| 226591_at | 26.339521 | SNRPN | 6638 | Small nuclear
ribonucleoprotein polypeptide N |
| 227491_at | 20.302715 | ELOVL6 | 79071 | ELOVL family member
6, elongation of long chain fatty acids (FEN1/Elo2, SUR4/Elo3-like,
yeast) |
| 227870_at | 48.255272 | IGDCC4 | 57722 | Immunoglobulin
superfamily, DCC subclass, member 4 |
| 227925_at | 65.23458 | FLJ39051 | 399972 | Hypothetical gene
supported by AK096370 |
| 227955_s_at | 29.176859 | EFNA5 | 1946 | Ephrin-A5 |
| 228007_at | 20.671658 | C6 or f204 | 387119 | Chromosome 6 open
reading frame 204 |
| 228072_at | 35.00761 | SYT12 | 91683 | Synaptotagmin
XII |
| 229228_at | 178.89961 | CREB5 | 9586 | cAMP responsive
element binding protein 5 |
| 229450_at | 20.979269 | IFIT3 | 3437 | Interferon-induced
protein with tetratricopeptide repeats 3 |
| 229478_x_at | 48.66807 | BIVM | 54841 | Basic,
immunoglobulin-like variable motif containing |
| 229518_at | 24.889814 | FAM46B | 115572 | Family with
sequence similarity 46, member B |
| 229579_s_at | 42.72015 | DISP2 | 85455 | Dispatched homolog
2 (Drosophila) |
| 229725_at | 30.584335 | ACSL6 | 23305 | Acyl-CoA synthetase
long-chain family member 6 |
| 230245_s_at | 25.038433 | LOC283663 | 283663 | Hypothetical
LOC283663 |
| 230487_at | 66.86591 | C6 or f99 | 100130967 | Chromosome 6 open
reading frame 99 |
| | LOC100130967 | 389440 | Similar to
hCG2044932 |
| 230615_at | 46.127205 | DUOXA2 | 405753 | Dual oxidase
maturation factor 2 |
| 230660_at | 37.561954 | SERTAD4 | 56256 | SERTA domain
containing 4 |
| 230781_at | 42.71768 | | | |
| 231102_at | 32.751915 | CROT | 54677 | Carnitine
O-octanoyltransferase |
| 231203_at | 35.097168 | LOC100129633 | 100129633 | Similar to
hCG1651427 |
| 231336_at | 55.55161 | CPNE4 | 131034 | Copine IV |
| 231598_x_at | 111.41086 | | | |
| 231899_at | 30.031355 | ZC3H12C | 85463 | Zinc finger
CCCH-type containing 12C |
| 232068_s_at | 20.96932 | TLR4 | 7099 | Toll-like receptor
4 |
| 232387_at | 23.740568 | AP1GBP1 | 11276 | AP1 γ subunit
binding protein 1 |
| 232585_at | 24.154518 | LOC100128729 | 100128729 | Similar to TLK2
protein |
| | LOC100134651 | 100134651 | Similar to TLK2
protein |
| | LOC731082 | 11011 | Similar to
serine/threonine-protein kinase tousled-like 2 (tousled-like kinase
2) |
| | TLK2 | 731082 | Tousled-like kinase
2 |
| 233149_at | 20.532196 | | | |
| 233372_at | 48.244698 | | | |
| 233884_at | 21.642752 | HIVEP3 | 59269 | Human
immunodeficiency virus type I enhancer binding protein 3 |
| 233902_at | 35.82076 | GUCA1C | 9626 | Guanylate cyclase
activator 1C |
| 233984_at | 22.362148 | | | |
| 234700_s_at | 146.27199 | RNASE7 | 84659 | Ribonuclease, RNase
A family, 7 |
| 234980_at | 55.37136 | TMEM56 | 148534 | Transmembrane
protein 56 |
| 235795_at | 27.020695 | PAX6 | 5080 | Paired box 6 |
| 236302_at | 21.677221 | PPM1E | 22843 | Protein phosphatase
1E (PP2C domain containing) |
| 236365_at | 31.352936 | | | |
| 236522_at | 25.091562 | | | |
| 236542_at | 42.33878 | | | |
| 236740_at | 25.037415 | | | |
| 236801_at | 50.310337 | | | |
| 237250_at | 49.111843 | | | |
| 237406_at | 28.270689 | NEK6 | 10783 | NIMA (never in
mitosis gene a)-related kinase 6 |
| 237950_s_at | 49.878513 | | | |
| 237974_at | 36.01243 | ABHD12B | 145447 | Abhydrolase domain
containing 12B |
| 237996_at | 54.733566 | | | |
| 238088_at | 20.880829 | LOC100129194 | 100129194 | Hypothetical
protein LOC100129194 |
| 238363_at | 29.599056 | | | |
| 238520_at | 45.876377 | TRERF1 | 55809 | Transcriptional
regulating factor 1 |
| 238611_at | 22.46198 | | | |
| 239381_at | 61.001457 | KLK7 | 5650 | Kallikrein-related
peptidase 7 |
| 240214_at | 27.089334 | | | |
| 241044_x_at | 37.12408 | | | |
| 241579_at | 40.58749 | | | |
| 241814_at | 28.057734 | | | |
| 241842_x_at | 27.38526 | C19 or f45 | 374877 | Chromosome 19 open
reading frame 45 |
| 242003_at | 35.487854 | ERICH1 | 157697 | Glutamate-rich
1 |
| 242138_at | 27.004044 | DLX1 | 1745 | Distal-less
homeobox 1 |
| 242249_at | 21.104935 | | | |
| 242316_at | 25.703829 | | | |
| 242509_at | 26.935835 | | | |
| 242769_at | 26.859947 | | | |
| 242791_at | 26.823769 | FBXO3 | 26273 | F-box protein
3 |
| 242893_at | 28.790308 | | | |
| 243753_at | 20.372232 | C1 or f173 | 127254 | Chromosome 1 open
reading frame 173 |
| 244016_at | 41.27944 | | | |
| 244639_at | 20.593792 | | | |
| 244785_at | 25.557535 | | | |
| 1552480_s_at | 27.07572 | PTPRC | 5788 | Protein tyrosine
phosphatase, receptor type, C |
| 1552580_at | 30.773138 | TRIML2 | 205860 | Tripartite motif
family-like 2 |
| 1552904_at | 26.276854 | NETO1 | 81832 | Neuropilin (NRP)
and tolloid (TLL)-like 1 |
| 1552987_a_at | 41.45497 | MGC42157 | 439933 | Hypothetical locus
MGC42157 |
| 1553037_a_at | 22.476143 | SYN2 | 6854 | Synapsin II |
| 1553315_at | 22.418777 | SLFNL1 | 200172 | Schlafen-like
1 |
| 1553635_s_at | 22.641033 | TCTEX1D1 | 200132 | Tctex1 domain
containing 1 |
| 1553789_a_at | 27.130203 | C21 or f58 | 54058 | Chromosome 21 open
reading frame 58 |
| 1554001_at | 49.381943 | TRIM37 | 4591 | Tripartite
motif-containing 37 |
| 1554398_at | 27.990637 | LYG2 | 254773 | Lysozyme G-like
2 |
| 1554512_a_at | 40.911217 | CCDC123 | 84902 | Coiled-coil domain
containing 123 |
| 1555300_a_at | 25.510637 | MED12L | 116931 | Mediator complex
subunit 12-like |
| 1555717_at | 38.556057 | | | |
| 1555912_at | 33.604454 | ST7OT1 | 93653 | ST7 overlapping
transcript 1 (non-protein coding) |
| 1556008_a_at | 36.32589 | | | |
| 1556202_at | 39.568478 | SRGAP2 | 23380 | SLIT-ROBO Rho
GTPase activating protein 2 |
| 1556541_s_at | 29.452276 | | | |
| 1558552_s_at | 20.966536 | C3 or f55 | 152078 | Chromosome 3 open
reading frame 55 |
| 1558234_at | 31.376406 | FLJ36644 | 400617 | Hypothetical
protein LOC400617 |
| 1558791_at | 43.679718 | LOC286467 | 286467 | Hypothetical
LOC286467 |
| 1561114_a_at | 22.05421 | DEPDC4 | 120863 | DEP domain
containing 4 |
| 1560048_at | 27.137468 | | | |
| 1561101_at | 35.96605 | LOC153469 | 153469 | Hypothetical
protein LOC153469 1561260_at 23.416117 |
| 1561573_at | 23.90905 | | | |
| 1561714_a_at | 41.711376 | B3GALNT2 | 148789 |
β-1,3-N-acetylgalactosaminyltransferase
2 |
| 1561731_at | 49.069042 | | | |
| 1561918_at | 21.02261 | | | |
| 1562860_at | 40.932205 | | | |
| 1562990_at | 26.946367 | | | |
| 1563392_at | 23.033009 | | | |
| 1563456_at | 25.698204 | CCDC141 | 285025 | Coiled-coil domain
containing 141 |
| | LOC285026 | 285026 | Hypothetical
protein LOC285026 |
| 1564653_s_at | 35.795006 | LEKR1 | 389170 | Leucine, glutamate
and lysine rich 1 |
| 1564932_at | 21.246243 | | | |
| 1565337_at | 22.219374 | DNAH6 | 1768 | Dynein, axonemal,
heavy chain 6 |
| 1568941_a_at | 24.125954 | | | |
| 1569408_at | 27.472164 | EIF2C4 | 192670 | Eukaryotic
translation initiation factor 2C, 4 |
| 1569599_at | 47.001877 | SAMSN1 | 64092 | SAM domain, SH3
domain and nuclear localization signals 1 |
| 1569772_x_at | 23.892517 | | | |
| 1569832_at | 34.25927 | hCG_2045206 | 100131655 | Hypothetical
LOC100131655 |
| 1569948_at | 21.763708 | | | |
| 1570076_at | 30.77381 | | | |
 | Table IIGenes differentially expressed in the
primary colon carcinoma specimen and its paired hepatic
metastasis. |
Table II
Genes differentially expressed in the
primary colon carcinoma specimen and its paired hepatic
metastasis.
| Probe set ID | Fold change | Gene symbol | Entrez gene | Gene title |
|---|
| 201744_s_at | 109.43063 | LUM | 4060 | Lumican |
| 203639_s_at | 39.816193 | FGFR2 | 2263 | Fibroblast growth
factor receptor 2 |
| 203687_at | 23.863962 | CX3CL1 | 6376 | Chemokine (C-X3-C
motif) ligand 1 |
| 203697_at | 55.182484 | FRZB | 2487 | Frizzled-related
protein |
| 203817_at | 36.81657 | GUCY1B3 | 2983 | Guanylate cyclase
1, soluble, β 3 |
| 204010_s_at | 40.820312 | KRAS | 3845 | v-Ki-ras2 Kirsten
rat sarcoma viral oncogene homolog |
| 204439_at | 50.40096 | IFI44L | 10964 | Interferon-induced
protein 44-like |
| 204646_at | 73.7989 | DPYD | 1806 | Dihydropyrimidine
dehydrogenase |
| 204704_s_at | 30.57162 | ALDOB | 229 | Aldolase B,
fructose-bisphosphate |
| 205830_at | 40.507374 | CLGN | 1047 | Calmegin |
| 205893_at | 33.37443 | NLGN1 | 22871 | Neuroligin 1 |
| 206091_at | 43.29831 | MATN3 | 4148 | Matrilin 3 |
| 206218_at | 29.100803 | MAGEB2 | 4113 | Melanoma antigen
family B, 2 |
| 207349_s_at | 24.040384 | UCP3 | 7352 | Uncoupling protein
3 (mitochondrial, proton carrier) |
| 207583_at | 27.094574 | ABCD2 | 225 | ATP-binding
cassette, sub-family D (ALD), member 2 |
| 207750_at | 29.539001 | EPS15L2 | 55380 | Epidermal growth
factor receptor pathway substrate 15-like 2 |
| 208250_s_at | 34.10199 | DMBT1 | 1755 | Deleted in
malignant brain tumors 1 |
| 210077_s_at | 23.053602 | SFRS5 | 6430 | Splicing factor,
arginine/serine-rich 5 |
| 210143_at | 36.192024 | ANXA10 | 11199 | Annexin A10 |
| 210510_s_at | 52.630417 | NRP1 | 8829 | Neuropilin 1 |
| 210571_s_at | 69.8555 | CMAH | 8418 | Cytidine
monophosphate-N-acetylneuraminic acid hydroxylase
(CMP-N-acetylneuraminate monooxygenase) pseudogene |
| 211204_at | 21.602095 | ME1 | 4199 | Malic enzyme 1,
NADP(+)-dependent, cytosolic |
| 211842_s_at | 20.652378 | SLC24A1 | 9187 | Solute carrier
family 24 (sodium/potassium/calcium exchanger), member 1 |
| 212768_s_at | 68.42675 | OLFM4 | 10562 | Olfactomedin 4 |
| 213496_at | 31.919434 | LPPR4 | 9890 | Plasticity related
gene 1 |
| 213519_s_at | 26.87308 | LAMA2 | 3908 | Laminin, α 2 |
| 214044_at | 35.559616 | RYR2 | 6262 | Ryanodine receptor
2 (cardiac) |
| 214121_x_at | 29.512691 | PDLIM7 | 9260 | PDZ and LIM domain
7 (enigma) |
| 214146_s_at | 50.72601 | PPBP | 5473 | Pro-platelet basic
protein [chemokine (C-X-C motif) ligand 7] |
| 214567_s_at | 24.816338 | XCL1 | 6375 | Chemokine (C motif)
ligand 1 |
| | XCL2 | 6846 | Chemokine (C motif)
ligand 2 |
| 214823_at | 45.280537 | ZNF204 | 7754 | Zinc finger protein
204 pseudogene |
| 215172_at | 35.013386 | PTPN20A | 26095 | Protein tyrosine
phosphatase, non-receptor type 20A |
| | PTPN20B | 653129 | Protein tyrosine
phosphatase, non-receptor type 20B |
| 216236_s_at | 22.056973 | SLC2A14 | 144195 | Solute carrier
family 2 (facilitated glucose transporter) |
| | SLC2A3 | 6515 | Member 14/solute
carrier family 2 (facilitated glucose transporter) member 3 |
| 216918_s_at | 22.751093 | DST | 667 | Dystonin |
| 217549_at | 33.947136 | | | |
| 217584_at | 28.199327 | | | |
| 219396_s_at | 51.44716 | NEIL1 | 79661 | Nei endonuclease
VIII-like 1 (E. coli) |
| 219938_s_at | 38.966156 | PSTPIP2 | 9050 |
Proline-serine-threonine phosphatase
interacting protein 2 |
| 219947_at | 42.138695 | CLEC4A | 50856 | C-type lectin
domain family 4, member A |
| 219949_at | 40.146168 | LRRC2 | 79442 | Leucine-rich repeat
containing 2 |
| 220253_s_at | 49.8748 | LRP12 | 29967 | Low density
lipoprotein-related protein 12 |
| 220333_at | 24.75799 | PAQR5 | 54852 | Progestin and
adipoQ receptor family member V |
| 220858_at | 40.026302 | SORBS2 | 8470 | Sorbin and SH3
domain containing 2 |
| 222249_at | 32.831154 | | | |
| 222664_at | 57.42625 | KCTD15 | 79047 | Potassium channel
tetramerisation domain containing 15 |
| 222720_x_at | 37.01965 | C1 or f27 | 54953 | Chromosome 1 open
reading frame 27 |
| 222738_at | 49.0615 | WWC2 | 80014 | WW and C2 domain
containing 2 |
| 223235_s_at | 83.11333 | SMOC2 | 64094 | SPARC related
modular calcium binding 2 |
| 223553_s_at | 60.20032 | DOK3 | 79930 | Docking protein
3 |
| 223645_s_at | 23.843172 | CYorf15B | 84663 | Chromosome Y open
reading frame 15B |
| 223985_at | 25.144203 | FSD1L | 83856 | Fibronectin type
III and SPRY domain containing 1-like |
| 223999_at | 43.358845 | PPIL2 | 23759 | Peptidylprolyl
isomerase (cyclophilin)-like 2 |
| 224029_x_at | 53.921314 | SCN11A | 11280 | Sodium channel,
voltage-gated, type XI, α subunit |
| 224135_at | 28.728426 | WDR87 | 83889 | WD repeat domain
87 |
| 224370_s_at | 51.475292 | CAPS2 | 84698 | Calcyphosine 2 |
| 224533_s_at | 75.15053 | C6 or f142 | 90523 | Chromosome 6 open
reading frame 142 |
| 225627_s_at | 20.237694 | CACHD1 | 57685 | Cache domain
containing 1 |
| 225728_at | 45.161 | SORBS2 | 8470 | Sorbin and SH3
domain containing 2 |
| 226147_s_at | 64.73383 | PIGR | 5284 | Polymeric
immunoglobulin receptor |
| 226425_at | 21.041115 | CLIP4 | 79745 | CAP-GLY domain
containing linker protein family, member 4 |
| 226435_at | 23.594818 | PAPLN | 89932 | Papilin,
proteoglycan-like sulfated glycoprotein |
| 226591_at | 29.041143 | SNRPN | 6638 | Small nuclear
ribonucleoprotein polypeptide N |
| 227826_s_at | 47.852997 | | | |
| 227925_at | 29.181805 | FLJ39051 | 399972 | Hypothetical gene
supported by AK096370 |
| 228007_at | 23.74942 | C6 or f204 | 387119 | Chromosome 6 open
reading frame 204 |
| 228255_at | 23.693722 | ALS2CR4 | 65062 | Amyotrophic lateral
sclerosis 2 (juvenile) chromosome region, candidate 4 |
| 228766_at | 35.04908 | CD36 | 948 | CD36 molecule
(thrombospondin receptor) |
| 229495_at | 24.522652 | PM20D2 | 135293 | Peptidase M20
domain containing 2 |
| 230245_s_at | 35.8261 | LOC283663 | 283663 | Hypothetical
LOC283663 |
| 230720_at | 20.412619 | RNF182 | 221687 | Ring finger protein
182 |
| 231102_at | 126.71907 | CROT | 54677 | Carnitine
O-octanoyltransferase |
| 231114_at | 49.288345 | SPATA22 | 84690 | Spermatogenesis
associated 22 |
| 231385_at | 37.57739 | DPPA3 | 359787 | Developmental
pluripotency associated 3 |
| 231560_at | 24.556393 | | | |
| 231969_at | 32.270084 | STOX2 | 56977 | Storkhead box
2 |
| 232049_at | 20.035376 | | | |
| 232090_at | 21.041267 | LOC100128178 | 100128178 | Similar to
hCG2041313 |
| 232397_at | 116.284195 | | | |
| 232481_s_at | 28.357405 | SLITRK6 | 84189 | SLIT and NTRK-like
family, member 6 |
| 232641_at | 30.381804 | ZNF596 | 169270 | Zinc finger protein
596 |
| 233721_x_at | 38.845203 | | | |
| 233814_at | 50.578884 | EFNA5 | 1946 | Ephrin-A5 |
| 233871_at | 42.2906 | | | |
| 233934_at | 24.12915 | LOC349160 | 349160 | Hypothetical
protein LOC349160 |
| 234030_at | 36.926117 | | | |
| 234980_at | 21.773212 | TMEM56 | 148534 | Transmembrane
protein 56 |
| 235306_at | 22.31179 | GIMAP8 | 155038 | GTPase, IMAP family
member 8 |
| 236220_at | 39.285076 | | | |
| 236365_at | 38.961994 | | | |
| 236698_at | 21.145327 | | | |
| 236740_at | 21.301474 | | | |
| 237150_at | 21.254215 | | | |
| 237427_at | 20.181032 | | | |
| 237905_at | 23.934755 | KRT25 | 147183 | Keratin 25 |
| 238009_at | 20.990005 | | | |
| 238751_at | 38.94119 | | | |
| 239443_at | 26.224146 | PCDHB6 | 56130 | Protocadherin β
6 |
| 239447_at | 44.547733 | TRA2B | 6434 | Transformer 2 β
homolog (Drosophila) |
| 239477_at | 24.663624 | EFHB | 151651 | EF-hand domain
family, member B |
| 239698_at | 24.539743 | | | |
| 240120_at | 20.922508 | | | |
| 240214_at | 31.374973 | | | |
| 240466_at | 24.025442 | | | |
| 240964_at | 21.602964 | | | |
| 241829_at | 27.049297 | FAM124A | 220108 | Family with
sequence similarity 124A |
| 241926_s_at | 51.05444 | ERG | 2078 | v-ets
erythroblastosis virus E26 oncogene homolog (avian) |
| 242003_at | 20.770477 | ERICH1 | 157697 | Glutamate-rich
1 |
| 242249_at | 41.35373 | | | |
| 242340_at | 33.86683 | | | |
| 242721_at | 46.80031 | | | |
| 242893_at | 42.70509 | | | |
| 243500_at | 30.1103 | CASD1 | 64921 | CAS1 domain
containing 1 |
| 243746_at | 45.71318 | IGHMBP2 | 3508 | Immunoglobulin mu
binding protein 2 |
| 243901_at | 28.134262 | ALDOB | 229 | Aldolase B,
fructose-bisphosphate |
| 244531_at | 61.498493 | NNT | 23530 | Nicotinamide
nucleotide transhydrogenase |
| 1552835_at | 21.108583 | DENND1B | 163486 | DENN/MADD domain
containing 1B |
| 1552927_at | 22.232943 | MAP3K7IP3 | 257397 | Mitogen-activated
protein kinase kinase kinase 7 interacting protein 3 |
| 1552999_a_at | 27.387323 | WFDC10B | 280664 | WAP four-disulfide
core domain 10B |
| 1554176_a_at | 23.11273 | C3 or f33 | 285315 | Chromosome 3 open
reading frame 33 |
| 1554001_at | 41.838184 | TRIM37 | 4591 | Tripartite
motif-containing 37 |
| 1554398_at | 24.453304 | LYG2 | 254773 | Lysozyme G-like
2 |
| 1555912_at | 44.85555 | ST7OT1 | 93653 | ST7 overlapping
transcript 1 (non-protein coding) |
| 1556008_a_at | 47.270073 | | | |
| 1556203_a_at | 30.X93089 | SRGAP2 | 23380 | SLIT-ROBO Rho
GTPase activating protein 2 |
| 1556289_at | 20.807093 | | | |
| 1556357_s_at | 26.665522 | ERICH1 | 157697 | Glutamate-rich
1 |
| 1556392_a_at | 22.948168 | | | |
| 1556393_at | 36.13576 | | | |
| 1557520_a_at | 24.872932 | | | |
| 1558135_at | 25.871822 | TAF11 | 6882 | TAF11 RNA
polymerase II, TATA box binding protein (TBP)-associated factor, 28
kDa |
| 1558234_at | 55.475685 | FLJ36644 | 400617 | Hypothetical
protein LOC400617 |
| 1558574_at | 26.385082 | | | |
| 1558606_s_at | 20.5551 | | | |
| 1558693_s_at | 29.909445 | C1 or f85 | 112770 | Chromosome 1 open
reading frame 85 |
| 1558815_at | 49.138927 | SORBS2 | 8470 | Sorbin and SH3
domain containing 2 |
| 1558934_a_at | 37.3662 | GTF2H5 | 404672 | General
transcription factor IIH, polypeptide 5 |
| 1560048_at | 32.75761 | | | |
| 1560422_at | 45.097427 | | | |
| 1561432_at | 23.945683 | | | |
| 1561882_at | 42.562286 | SYTL3 | 94120 | Synaptotagmin-like
3 |
| 1562094_at | 28.180384 | | | |
| 1562294_x_at | 22.353355 | ANKRD30B | 374860 | Ankyrin repeat
domain 30B |
| 1562310_at | 22.610895 | | | |
| 1562472_at | 26.148716 | | | |
| 1562742_at | 59.214592 | | | |
| 1562860_at | 21.426584 | | | |
| 1563112_at | 76.9244 | FAM120AOS | 158293 | Family with
sequence similarity 120A opposite strand |
| 1564039_at | 24.121265 | ZSCAN23 | 222696 | Zinc finger and
SCAN domain containing 23 |
| 1568012_at | 31.55809 | CLIP1 | 6249 | CAP-GLY domain
containing linker protein 1 |
| 1570600_at | 22.040146 | | | |
 | Table IIIGenes differentially expressed in the
colon carcinoma lymphatic metastasis specimen and the hepatic
metastasis specimen. |
Table III
Genes differentially expressed in the
colon carcinoma lymphatic metastasis specimen and the hepatic
metastasis specimen.
| Probe set ID | Fold change | Gene symbol | Entrez gene | Gene title |
|---|
| 203323_at | 17.572113 | CAV2 | 858 | Caveolin 2 |
| 203324_s_at | 12.488382 | CAV2 | 858 | Caveolin 2 |
| 203372_s_at | 38.86711 | SOCS2 | 8835 | Suppressor of
cytokine signaling 2 |
| 203543_s_at | 11.408775 | KLF9 | 687 | Kruppel-like factor
9 |
| 203561_at | 28.196625 | FCGR2A | 2212 | Fc fragment of IgG,
low affinity IIa, receptor (CD32) |
| 203835_at | 11.724807 | LRRC32 | 2615 | Leucine-rich repeat
containing 32 |
| 204035_at | 22.833523 | SCG2 | 7857 | Secretogranin II
(chromogranin C) |
| 204069_at | 18.195318 | MEIS1 | 4211 | Meis homeobox
1 |
| 204682_at | 12.34678 | LTBP2 | 4053 | Latent transforming
growth factor β binding protein 2 |
| 204802_at | 34.692444 | RRAD | 6236 | Ras-related
associated with diabetes |
| 205610_at | 55.83588 | MYOM1 | 8736 | Myomesin 1, 185
kDa |
| 205692_s_at | 10.167213 | CD38 | 952 | CD38 molecule |
| 205943_at | 17.091461 | TDO2 | 6999 | Tryptophan
2,3-dioxygenase |
| 206022_at | 31.875471 | NDP | 4693 | Norrie disease
(pseudoglioma) |
| 206025_s_at | 11.98506 | TNFAIP6 | 7130 | Tumor necrosis
factor, α-induced protein 6 |
| 206143_at | 17.525316 | SLC26A3 | 1811 | Solute carrier
family 26, member 3 |
| 206488_s_at | 21.102892 | CD36 | 948 | CD36 molecule
(thrombospondin receptor) |
| 206654_s_at | 10.075909 | POLR3G | 10622 | Polymerase (RNA)
III (DNA directed) polypeptide G (32 kD) |
| 207089_at | 34.273483 | NRAP | 4892 | Nebulin-related
anchoring protein |
| 207501_s_at | 19.537613 | FGF12 | 2257 | Fibroblast growth
factor 12 |
| 207580_at | 22.841743 | MAGEB4 | 4115 | Melanoma antigen
family B, 4 |
| 208086_s_at | 25.490797 | DMD | 1756 | Dystrophin |
| 208259_x_at | 18.155922 | IFNA7 | 3444 | Interferon, α
7 |
| 209576_at | 32.88002 | GNAI1 | 2770 | Guanine nucleotide
binding protein (G protein), α inhibiting activity polypeptide
1 |
| 209652_s_at | 12.313976 | PGF | 5228 | Placental growth
factor |
| 209700_x_at | 25.640623 | PDE4DIP | 9659 | Phosphodiesterase
4D interacting protein |
| 209776_s_at | 13.3636875 | SLC19A1 | 6573 | Solute carrier
family 19 (folate transporter), member 1 |
| 209821_at | 20.940786 | IL33 | 90865 | Interleukin 33 |
| 210077_s_at | 24.33262 | SFRS5 | 6430 | Splicing factor,
arginine/serine-rich 5 |
| 210948_s_at | 21.301382 | LEF1 | 51176 | Lymphoid
enhancer-binding factor 1 |
| 211190_x_at | 22.055872 | CD84 | 8832 | CD84 molecule |
| 213423_x_at | 10.081812 | TUSC3 | 7991 | Tumor suppressor
candidate 3 |
| 213428_s_at | 13.616949 | COL6A1 | 1291 | Collagen, type VI,
α 1 |
| 214998_at | 31.85507 | AAK1 | 22848 | AP2 associated
kinase 1 |
| 215495_s_at | 14.478629 | SAMD4A | 23034 | Sterile α motif
domain containing 4A |
| 215513_at | 17.604755 | HYMAI | 57061 | Hydatidiform mole
associated and imprinted (non-protein coding) |
| 215657_at | 12.403633 | SLC26A3 | 1811 | Solute carrier
family 26, member 3 |
| 216466_at | 13.427488 | NAV3 | 89795 | Neuron navigator
3 |
| 216589_at | 10.48587 | LOC390998 | 390998 | Similar to
hCG1644589 |
| 216695_s_at | 18.244976 | TNKS | 8658 | Tankyrase,
TRF1-interacting ankyrin-related ADP-ribose polymerase |
| 216757_at | 10.563152 | | | |
| 217157_x_at | 15.075894 | IGK | 3514 | Immunoglobulin κ
locus |
| | IGKC | 50802 | Immunoglobulin κ
constant |
| | LOC647506 | 647506 | Similar to Ig κ
chain V-I region HK101 precursor |
| | LOC650405 | 650405 | Similar to Ig κ
chain V-I region HK102 precursor |
| | LOC652493 | 652493 | Similar to Ig κ
chain V-I region HK102 precursor |
| 217321_x_at | 28.0056 | ATXN3 | 4287 | Ataxin 3 |
| 217665_at | 12.379506 | | | |
| 218638_s_at | 17.851858 | SPON2 | 10417 | Spondin 2,
extracellular matrix protein |
| 220858_at | 19.423872 | SORBS2 | 8470 | Sorbin and SH3
domain containing 2 |
| 220906_at | 20.039635 | | | |
| 221154_at | 38.946198 | TRIM49 | 57093 | Tripartite
motif-containing 49 |
| 221541_at | 11.172807 | CRISPLD2 | 83716 | Cysteine-rich
secretory protein LCCL domain containing 2 |
| 221558_s_at | 10.16347 | LEF1 | 51176 | Lymphoid
enhancer-binding factor 1 |
| 31835_at | 11.370078 | HRG | 3273 | Histidine-rich
glycoprotein |
| 223599_at | 12.111252 | TRIM6 | 117854 | Tripartite
motif-containing 6 |
| 223812_at | 13.24775 | FAM178B | 51252 | Family with
sequence similarity 178, member B |
| 223876_at | 11.548148 | SPATA16 | 83893 | Spermatogenesis
associated 16 |
| 224024_at | 22.182268 | ERGIC1 | 57222 | Endoplasmic
reticulum-golgi intermediate compartment (ERGIC) 1 |
| 224056_at | 17.563913 | | | |
| 225029_at | 15.641858 | LOC550643 | 550643 | Hypothetical
LOC550643 |
| 225288_at | 11.822223 | COL27A1 | 85301 | Collagen, type
XXVII, α 1 |
| 226147_s_at | 150.0156 | PIGR | 5284 | Polymeric
immunoglobulin receptor |
| 226828_s_at | 29.641703 | HEYL | 26508 |
Hairy/enhancer-of-split related with YRPW
motif-like |
| 227692_at | 20.724081 | GNAI1 | 2770 | Guanine nucleotide
binding protein (G protein), α inhibiting activity polypeptide
1 |
| 228167_at | 34.570217 | KLHL6 | 89857 | Kelch-like 6
(Drosophila) |
| 228275_at | 21.79044 | | | |
| 228547_at | 23.981333 | NRXN1 | 9378 | Neurexin 1 |
| 229051_at | 26.098585 | | | |
| 229085_at | 12.635592 | LRRC3B | 116135 | Leucine-rich repeat
containing 3B |
| 229199_at | 10.150482 | SCN9A | 6335 | Sodium channel,
voltage-gated, type IX, α subunit |
| 229228_at | 52.54796 | CREB5 | 9586 | cAMP responsive
element binding protein 5 |
| 229381_at | 11.871673 | C1 or f64 | 149563 | Chromosome 1 open
reading frame 64 |
| 229518_at | 28.762573 | FAM46B | 115572 | Family with
sequence similarity 46, member B |
| 229659_s_at | 20.485302 | | | |
| 229725_at | 29.211315 | ACSL6 | 23305 | Acyl-CoA synthetase
long-chain family member 6 |
| 229968_at | 13.312329 | | | |
| 230261_at | 16.136084 | ST8SIA4 | 7903 | ST8
α-N-acetyl-neuraminide α-2,8-sialyltransferase 4 |
| 230351_at | 10.333499 | LOC283481 | 283481 | Hypothetical
protein LOC283481 |
| 230615_at | 19.222267 | DUOXA2 | 405753 | Dual oxidase
maturation factor 2 |
| 230781_at | 28.851234 | | | |
| 230943_at | 13.1987 | SOX17 | 64321 | SRY (sex
determining region Y)-box 17 |
| 231749_at | 11.926773 | TIMM13 | 26517 | Translocase of
inner mitochondrial membrane 13 homolog (yeast) |
| 231964_at | 27.403822 | | | |
| 232113_at | 42.29946 | | | |
| 232378_at | 14.133439 | SLC5A9 | 200010 | Solute carrier
family 5 (sodium/glucose cotransporter), member 9 |
| 232408_at | 11.252221 | ZFYVE28 | 57732 | Zinc finger, FYVE
domain containing 28 |
| 232673_at | 15.140463 | LRRFIP2 | 9209 | Leucine-rich repeat
(in FLII) interacting protein 2 |
| 233586_s_at | 23.207222 | KLK12 | 43849 | Kallikrein-related
peptidase 12 |
| 233934_at | 20.81878 | LOC349160 | 349160 | Hypothetical
protein LOC349160 |
| 234233_s_at | 15.17553 | | | |
| 235334_at | 15.941539 | ST6GALNAC3 | 256435 | ST6
(α-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3)-N-acetylgalactosaminide
α-2,6-sialyltransferase 3 |
| 235764_at | 17.735975 | | | |
| 236105_at | 11.190036 | | | |
| 236191_at | 34.859856 | | | |
| 236762_at | 13.769478 | ATP9B | 374868 | ATPase, class II,
type 9B |
| 236801_at | 14.398608 | | | |
| 237452_at | 13.013656 | | | |
| 237608_at | 11.315111 | | | |
| 238281_at | 17.088953 | | | |
| 238283_at | 11.590735 | LOC151658 | 151658 | Hypothetical
LOC151658 |
| 238625_at | 27.370302 | C1orf168 | 199920 | Chromosome 1 open
reading frame 168 |
| 238634_x_at | 12.341533 | | | |
| 238876_at | 14.355665 | | | |
| 239506_s_at | 30.187277 | LOC151300 | 151300 | Hypothetical
LOC151300 |
| 239823_at | 10.645902 | | | |
| 239883_s_at | 47.341763 | ANO4 | 121601 | Anoctamin 4 |
| 239995_at | 20.010996 | | | |
| 240212_at | 19.915565 | | | |
| 240334_at | 11.40588 | | | |
| 240856_at | 22.449312 | | | |
| 241308_at | 10.37427 | LOC729589 | 729589 | Hypothetical
LOC729589 |
| 241765_at | 33.79925 | CPM | 1368 | Carboxypeptidase
M |
| 241841_at | 16.08523 | | | |
| 242006_at | 12.057802 | LCA5 | 167691 | Leber congenital
amaurosis 5 |
| 242034_at | 37.776375 | FBXL17 | 64839 | F-box and
leucine-rich repeat protein 17 |
| 242193_at | 10.155277 | LOC100130155 | 100130155 | Hypothetical
protein LOC100130155 |
| 242246_x_at | 17.554796 | | | |
| 242316_at | 27.534788 | | | |
| 242509_at | 21.54953 | | | |
| 242906_at | 27.747772 | | | |
| 242943_at | 14.356349 | ST8SIA4 | 7903 | ST8
α-N-acetyl-neuraminide α-2,8-sialyltransferase 4 |
| 243489_at | 14.7732115 | | | |
| 244009_at | 10.311149 | | | |
| 244074_at | 12.198139 | LOC100129104 | 100129104 | Similar to
hydroxyproline-rich glycoprotein VSP-3 |
| 244112_x_at | 17.781418 | | | |
| 1552440_at | 22.730635 | GPR182 | 11318 | G protein-coupled
receptor 182 |
| 1552463_at | 17.636255 | SERPINB11 | 89778 | Serpin peptidase
inhibitor, clade B (ovalbumin), member 11 (gene/pseudogene) |
| 1552584_at | 11.233118 | IL12RB1 | 3594 | Interleukin 12
receptor, β 1 |
| 1553470_at | 12.427377 | DNAH17 | 8632 | Dynein, axonemal,
heavy chain 17 |
| 1553626_a_at | 15.016963 | C17orf57 | 124989 | Chromosome 17 open
reading frame 57 |
| 1553970_s_at | 10.47964 | CEL | 1056 | Carboxyl ester
lipase (bile salt-stimulated lipase) |
| 1554037_a_at | 11.989659 | ZBTB24 | 9841 | Zinc finger and BTB
domain containing 24 |
| 1554277_s_at | 10.488272 | FANCM | 57697 | Fanconi anemia,
complementation group M |
| 1555745_a_at | 11.363364 | LYZ | 4069 | Lysozyme (renal
amyloidosis) |
| 1554672_at | 19.961636 | TTC26 | 79989 | Tetratricopeptide
repeat domain 26 |
| 1555002_at | 22.022196 | MGC39545 | 403312 | Hypothetical
protein LOC403312 |
| 1555022_at | 25.609352 | RGS12 | 6002 | Regulator of
G-protein signaling 12 |
| 1555339_at | 12.859835 | RAP1A | 5906 | RAP1A, member of
RAS oncogene family |
| 1555435_at | 36.40531 | AFF4 | 27125 | AF4/FMR2 family,
member 4 |
| 1556474_a_at | 52.13133 | FLJ38379 | 285097 | Hypothetical
FLJ38379 |
| 1556877_at | 25.908909 | | | |
| 1556898_at | 11.959699 | LOC200830 | 200830 | Hypothetical
protein LOC200830 |
| 1556905_at | 32.662815 | ZNF577 | 84765 | Zinc finger protein
577 |
| 1557581_x_at | 10.408871 | | | |
| 1557753_at | 14.301804 | | | |
| 1558452_at | 10.139205 | TMEM144 | 55314 | Transmembrane
protein 144 |
| 1558706_a_at | 18.524925 | ATOH8 | 84913 | Atonal homolog 8
(Drosophila) |
| 1558999_x_at | 17.685259 | LOC283922 | 283922 | Pyruvate
dehydrogenase phosphatase regulatory subunit pseudogene |
| | PDPR | 55066 | Pyruvate
dehydrogenase phosphatase regulatory subunit |
| 1559057_at | 13.380709 | | | |
| 1559101_at | 11.838457 | FYN | 2534 | FYN oncogene
related to SRC, FGR, YES |
| 1560756_at | 22.905785 | | | |
| 1560996_at | 22.832338 | | | |
| 1560999_a_at | 38.31254 | | | |
| 1561521_at | 27.853552 | S100B | 6285 | S100 calcium
binding protein B |
| 1561882_at | 37.053608 | SYTL3 | 94120 | Synaptotagmin-like
3 |
| 1562094_at | 12.56786 | | | |
| 1562165_at | 10.340052 | | | |
| 1562367_at | 17.341137 | C15 or f54 | 400360 | Chromosome 15 open
reading frame 54 |
| 1562528_at | 24.569925 | | | |
| 1562716_at | 11.445873 | LOC284632 | 284632 | Hypothetical
LOC284632 |
| 1562990_at | 15.226481 | | | |
| 1563061_at | 30.11877 | | | |
| 1563077_at | 14.259786 | | | |
| 1563612_at | 25.13671 | | | |
| 1563827_at | 13.029244 | LOC158434 | 158434 | Hypothetical
protein LOC158434 |
| 1564003_at | 17.397495 | | | |
| 1564294_at | 12.534436 | | | |
| 1564299_at | 25.326767 | LOC100127940 | 100127940 | Hypothetical
LOC100127940 |
| 1564386_at | 36.96616 | TXNDC8 | 255220 | Thioredoxin domain
containing 8 (spermatozoa) |
| 1564653_s_at | 17.913086 | LEKR1 | 389170 | Leucine, glutamate
and lysine rich 1 |
| 1565668_at | 15.500862 | TUBA1B | 10376 | Tubulin, α 1b |
| 1565755_at | 22.79346 | MAP1D | 254042 | Methionine
aminopeptidase 1D |
| 1566767_at | 12.185921 | | | |
| 1567702_at | 19.35184 | | | |
| 1568696_at | 24.071138 | ARMETL1 | 441549 | Arginine-rich,
mutated in early stage tumors-like 1 |
| 1569218_at | 40.51703 | | | |
| 1569408_at | 26.201654 | EIF2C4 | 192670 | Eukaryotic
translation initiation factor 2C, 4 |
| 1569788_at | 15.160305 | ST8SIA1 | 6489 | ST8
α-N-acetyl-neuraminide α-2,8-sialyltransferase 1 |
| 1570486_at | 12.096198 | SOX6 | 55553 | SRY (sex
determining region Y)-box 6 |
Discussion
The purpose of this study was to investigate the
heterogeneity in primary colon carcinoma and its corresponding
lymphatic and hepatic metastases using GeneChip HGU133Plus2.0
expression arrays (Affymetrix). Our results demonstrate that the
genome-wide gene expression varies between primary colon carcinoma
and its paired lymphatic and hepatic metastases. In our study, we
firstly demonstrate that a high degree of heterogeneity in gene
expression exists in primary colon carcinoma and corresponding
lymphatic and hepatic metastases.
The main purpose of investigating the heterogeneity
found in primary tumors and corresponding metastases is to evaluate
the effect of such heterogeneity on the efficacy of anticancer
therapy and cancer patient prognosis. As previously discussed
(1,16,18),
the patient-derived tumor tissue (PDTT) xenograft model, which has
a sound establishing method and a retained similarity to the
corresponding original donor tumors in histological presentation
and biological behavior, including protein expression, tumor
biomarker status and genomic and genetic status, has the potential
to be an ideal strategy to achieve our purpose. In our previous
study, we successfully established PDTT xenograft models of colon
carcinoma with lymphatic and hepatic metastases using the same
tissue samples from three above-mentioned tumor sites (16). The ideal biological characteristics
of such PDTT xenograft models, as previously described (16), led to the consideration that such
PDTT models may aid in the investigation of the underlying
mechanism of heterogeneity-related anticancer therapy response
differences in primary colon carcinoma and corresponding lymphatic
and hepatic metastases.
In conclusion, in this study, we investigated the
heterogeneity in primary colon carcinoma and corresponding
lymphatic and hepatic metastases focusing on genome-wide gene
expression, and revealed that there were differences in primary
colon carcinoma and matched lymphatic and hepatic metastases. In
subsequent studies, further investigation is required to ascertain
the heterogeneity of functional genes found in primary colon
carcinoma and paired lymphatic and hepatic metastases in a larger
group of patients with metastatic colon carcinoma, in order to
identify specific functional genes related to lymphatic and hepatic
metastases.
Acknowledgements
The present study was supported by the State Key
Basic Research and Development Program of China (973 Program, Grant
No. 2009CB521704), the National High-tech Research and Development
Program of China (863 Program, Grant No. 2006AA02A245), the
National Natural Science Foundation of China (Grant No. 81000894),
the Zhejiang Provincial Science and Technology Projects (Grant No.
2009C13021, 2011C23087), the Science Research Fund of Shaoxing
(Grant No. 2011D10013) and the Science Research Fund of Zhuji
(Grant No. 2011CC7874).
References
|
1
|
Jin KT, He KF, Teng F, Han N, Li GL, Xu ZZ
and Teng LS: Heterogeneity in primary tumors and corresponding
metastases: could it provide us with any hints to personalize
cancer therapy? Pers Med. 8:175–182. 2011. View Article : Google Scholar
|
|
2
|
Gong Y, Booser DJ and Sneige N: Comparison
of HER-2 status determined by fluorescence in situ hybridization in
primary and metastatic breast carcinoma. Cancer. 103:1763–1769.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gancberg D, Di Leo A, Cardoso F, Rouas G,
Pedrocchi M, Paesmans M, Verhest A, Bernard-Marty C, Piccart MJ and
Larsimont D: Comparison of HER-2 status between primary breast
cancer and corresponding distant metastatic sites. Ann Oncol.
13:1036–1043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Regitnig P, Schippinger W, Lindbauer M,
Samonigg H and Lax SF: Change of HER-2/neu status in a subset of
distant metastases from breast carcinomas. J Pathol. 203:918–926.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bozzetti C, Personeni N, Nizzoli R, Guazzi
A, Flora M, Bassano C, Negri F, Martella E, Naldi N, Franciosi V
and Cascinu S: HER-2/neu amplification by fluorescence in situ
hybridization in cytologic samples from distant metastatic sites of
breast carcinoma. Cancer. 99:310–315. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tanner M, Järvinen P and Isola J:
Amplification of HER-2/neu and topoisomerase IIalpha in primary and
metastatic breast cancer. Cancer Res. 61:5345–5348. 2001.PubMed/NCBI
|
|
7
|
Tapia C, Savic S, Wagner U, Schönegg R,
Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G,
Terracciano L, Feichter G and Bubendorf L: HER2 gene status in
primary breast cancers and matched distant metastases. Breast
Cancer Res. 9:R312007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Akcakanat A, Sahin A, Shaye AN, Velasco MA
and Meric-Bernstam F: Comparison of Akt/mTOR signaling in primary
breast tumors and matched distant metastases. Cancer.
112:2352–2358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu JM, Fackler MJ, Halushka MK, Molavi DW,
Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM,
Hicks JL, Chitale D, Ladanyi M, Sukumar S and Argani P:
Heterogeneity of breast cancer metastases: comparison of
therapeutic target expression and promoter methylation between
primary tumors and their multifocal metastases. Clin Cancer Res.
14:1938–1946. 2008. View Article : Google Scholar
|
|
10
|
Baldus SE, Schaefer KL, Engers R, Hartleb
D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of
KRAS, BRAF, and PIK3CA mutations in primary colorectal
adenocarcinomas and their corresponding metastases. Clin Cancer
Res. 16:790–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Molinari F, Martin V, Saletti P, De Dosso
S, Spitale A, Camponovo A, Bordoni A, Crippa S, Mazzucchelli L and
Frattini M: Differing deregulation of EGFR and downstream proteins
in primary colorectal cancer and related metastatic sites may be
clinically relevant. Br J Cancer. 100:1087–1094. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scartozzi M, Bearzi I, Berardi R,
Mandolesi A, Fabris G and Cascinu S: Epidermal growth factor
receptor (EGFR) status in primary colorectal tumors does not
correlate with EGFR expression in related metastatic sites:
implications for treatment with EGFR-targeted monoclonal
antibodies. J Clin Oncol. 22:4772–4778. 2004. View Article : Google Scholar
|
|
13
|
Scartozzi M, Bearzi I, Berardi R,
Mandolesi A, Pierantoni C and Cascinu S: Epidermal growth factor
receptor (EGFR) downstream signalling pathway in primary colorectal
tumours and related metastatic sites: optimising EGFR-targeted
treatment options. Br J Cancer. 97:92–97. 2007. View Article : Google Scholar
|
|
14
|
Sasatomi E, Finkelstein SD, Woods JD,
Bakker A, Swalsky PA, Luketich JD, Fernando HC and Yousem SA:
Comparison of accumulated allele loss between primary tumor and
lymph node metastasis in stage II non-small cell lung carcinoma:
implications for the timing of lymph node metastasis and prognostic
value. Cancer Res. 62:2681–2689. 2002.PubMed/NCBI
|
|
15
|
Park S, Holmes-Tisch AJ, Cho EY, Shim YM,
Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA and Ahn MJ:
Discordance of molecular biomarkers associated with epidermal
growth factor receptor pathway between primary tumors and lymph
node metastasis in non-small cell lung cancer. J Thorac Oncol.
4:809–815. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin K, Li G, Cui B, Zhang J, Lan H, Han N,
Xie B, Cao F, He K, Wang H, Xu Z, Teng L and Zhu T: Assessment of a
novel VEGF targeted agent using patient-derived tumor tissue
xenograft models of colon carcinoma with lymphatic and hepatic
metastases. PLoS One. 6:e283842011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fichtner I, Rolff J, Soong R, Hoffmann J,
Hammer S, Sommer A, Becker M and Merk J: Establishment of
patient-derived non-small cell lung cancer xenografts as models for
the identification of predictive biomarkers. Clin Cancer Res.
14:6456–6468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin KT, He KF, Li GL and Teng LS:
Personalized cancer therapy using a patient-derived tumor tissue
xenograft model: a translational field worthy of exploring further?
Pers Med. 7:597–606. 2010. View Article : Google Scholar
|